XOMA Royalty (NASDAQ:XOMA) Upgraded at Wall Street Zen

XOMA Royalty (NASDAQ:XOMA - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

A number of other analysts also recently issued reports on XOMA. Benchmark assumed coverage on shares of XOMA Royalty in a report on Thursday, April 17th. They set a "buy" rating and a $35.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $104.00 price objective on shares of XOMA Royalty in a research report on Wednesday, May 28th.

XOMA Royalty Stock Performance

Shares of NASDAQ XOMA traded down $0.34 during trading on Friday, reaching $23.93. 93,400 shares of the company traded hands, compared to its average volume of 31,900. The stock has a market cap of $286.44 million, a P/E ratio of -20.81 and a beta of 0.94. The firm's fifty day simple moving average is $24.09 and its 200 day simple moving average is $24.51. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 1.18. XOMA Royalty has a 12-month low of $18.35 and a 12-month high of $35.00.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.32. XOMA Royalty had a negative return on equity of 12.43% and a negative net margin of 13.04%. The company had revenue of $15.91 million during the quarter, compared to analysts' expectations of $6.75 million. As a group, research analysts anticipate that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Joseph M. Limber bought 17,935 shares of XOMA Royalty stock in a transaction on Thursday, April 3rd. The stock was acquired at an average price of $25.24 per share, with a total value of $452,679.40. Following the completion of the acquisition, the director now directly owns 16,524 shares of the company's stock, valued at $417,065.76. The trade was a -1,271.08% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CIO Bradley Sitko bought 4,134 shares of the firm's stock in a transaction dated Friday, March 21st. The stock was purchased at an average price of $23.89 per share, for a total transaction of $98,761.26. Following the transaction, the executive now owns 10,484 shares of the company's stock, valued at approximately $250,462.76. This represents a 65.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 29,312 shares of company stock valued at $735,061. 7.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XOMA. GAMMA Investing LLC raised its position in shares of XOMA Royalty by 1,063.8% in the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after buying an additional 1,585 shares during the last quarter. New York State Common Retirement Fund raised its holdings in XOMA Royalty by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after acquiring an additional 800 shares during the last quarter. Wells Fargo & Company MN lifted its stake in XOMA Royalty by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after purchasing an additional 1,183 shares in the last quarter. Deutsche Bank AG lifted its stake in XOMA Royalty by 5,087.9% in the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 6,309 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of XOMA Royalty by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock worth $205,000 after purchasing an additional 2,009 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.